This may well apply to a number of other cancer therapeutics given the recent report that GLI1-inducible glucuronidation imparts resistance to a broad spectrum of compounds including FDA-approved drugs such as methotrexate.19 Our observations warrant additional studies to appreciate the prevalence and the clinical implications of high UGT2B17 expression on outcomes of leukaemia patients. This evidence concerns the gene GLI1 and cancer.